Ligand ID: VDN


Drugbank ID:
DB00862
(Vardenafil)


Indication:
Used for the treatment of erectile dysfunction

Get human targets for VDN in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'VDN'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 10
ALA E 906
ILE E 905
ALA D 906
LEU D1178
PHE F 909
1.51A17.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		1x7q BETA-2-MICROGLOBULIN
HLA, A-11
(Homo
sapiens)		5 / 12
HIS B  84
ILE B  35
SER B  57
SER B  52
ILE A  23
1.75A15.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
MET A 130
SER A 144
MET A 165
GLN A 192
PHE A 185
1.78A21.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
PHE A 294
MET A   6
GLN A 127
GLY B1124
PHE A   8
1.75A22.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
REPLICASE
POLYPROTEIN 1AB,
LIGHT CHAIN
(SARSr-CoV)		5 / 10
LEU F 108
ALA F 155
ILE F 111
LEU B  22
MET B  67
1.59A19.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2ajf ACE2
(Homo
sapiens)		6 / 12
TYR B 381
LEU B 560
ALA B 384
VAL B 404
PHE B 525
ILE B 544
1.78A21.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2ajf ACE2
(Homo
sapiens)		5 / 10
LEU B 560
ALA B 396
VAL B 404
LEU B 320
MET B 383
1.52A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		2ajf ACE2
(Homo
sapiens)		5 / 12
HIS A 401
MET A 408
LEU A 554
MET A 383
MET A 323
1.63A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2bx4 3C-LIKE PROTEINASE
(SARS-COV
Sin2774)		5 / 10
TYR A 126
ALA A 173
LEU A 141
GLY A 149
PHE A 112
1.51A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
LEU S 374
ALA S 350
ALA S 508
LEU S 503
PHE S 501
1.63A18.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		5 / 10
LEU B  76
ILE B  70
LEU B  54
MET B  62
GLN B  63
1.64A19.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		5 / 12
TYR U  76
HIS U  83
ILE U  81
SER U  15
ILE U  38
1.67A16.00
None
ZN  U 998 (-3.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2gib NUCLEOCAPSID PROTEIN
(SARSr-CoV)		5 / 12
ILE A 305
LEU A 354
ILE A 358
ILE A 293
PHE A 287
1.47A15.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2gib NUCLEOCAPSID PROTEIN
(SARSr-CoV)		5 / 11
ILE A 305
LEU A 354
ILE A 358
ILE A 293
PHE A 287
1.47A15.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 10
LEU A 227
ILE A 222
VAL A 236
LEU A 214
PHE A 221
1.59A22.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2jw8 NUCLEOCAPSID PROTEIN
(SARSr-CoV)		5 / 12
LEU A 332
ALA B 337
ILE B 338
ILE B 321
PHE A 315
1.43A17.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		2jw8 NUCLEOCAPSID PROTEIN
(SARSr-CoV)		5 / 12
LEU A 354
ILE A 338
GLN B 261
PHE A 308
ILE A 305
1.54A15.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2jw8 NUCLEOCAPSID PROTEIN
(SARSr-CoV)		5 / 11
LEU A 332
ALA B 337
ILE B 338
ILE B 321
PHE A 315
1.43A17.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
ILE A 549
LEU A 537
ALA A 540
ILE A 573
PHE A 580
1.29A18.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 549
LEU A 537
ALA A 540
ILE A 573
PHE A 580
1.28A18.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2kqv NSP3
(SARSr-CoV)		5 / 12
ILE A  27
LEU A  15
ALA A  18
ILE A  51
PHE A  58
1.37A21.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2kqv NSP3
(SARSr-CoV)		5 / 11
ILE A  27
LEU A  15
ALA A  18
ILE A  51
PHE A  58
1.39A21.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2liz 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
TYR A 209
TYR A 239
ALA A 211
LEU A 287
MET A 276
1.64A17.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
ILE D 305
ILE D 235
VAL D 318
ILE D 327
PHE D 302
1.39A21.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
ILE D 305
ILE D 235
VAL D 318
ILE D 327
PHE D 302
1.39A21.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		5 / 10
TYR A 118
LEU A 115
MET A  17
GLN A  19
GLY A  29
1.77A22.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		2qc2 3C-LIKE PROTEINASE
(-)		5 / 12
MET A 130
SER A 144
MET A 165
GLN A 192
PHE A 185
1.49A21.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 10
TYR A 118
LEU A 115
MET A  17
GLN A  19
GLY A  29
1.74A21.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 10
LEU C 227
ILE C 222
VAL C 236
LEU C 214
PHE C 221
1.64A23.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
ILE F 306
LEU F 227
ILE F 222
VAL F 338
PHE F 232
1.46A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
ILE F 306
LEU F 297
ILE F 295
VAL F 236
PHE F 232
1.40A21.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2rnk REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
ILE A 549
LEU A 537
ALA A 540
ILE A 573
PHE A 580
1.42A18.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		2rnk REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
ILE A 549
LEU A 537
ALA A 540
ILE A 573
PHE A 580
1.41A18.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		2xyq NSP10
(SARSr-CoV)		5 / 12
HIS B  83
LEU B 112
ILE B  81
SER B  15
ILE B  38
1.67A15.01
 ZN  B1132 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		2xyv NSP10
(SARSr-CoV)		5 / 12
HIS B  83
LEU B 112
ILE B  81
SER B  15
ILE B  38
1.66A15.01
 ZN  B1130 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
TYR B 381
HIS B 401
MET B 408
LEU B 554
MET B 383
1.68A19.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
LEU B 560
ALA B 396
VAL B 404
LEU B 320
MET B 383
1.53A21.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
HIS B 373
LEU B 418
ILE B 291
ILE B 446
GLN B 442
1.54A21.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
TYR B 521
PHE B 525
LEU B 554
MET B 408
GLY B 377
1.60A21.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3i6g HLA, A-2
(Homo
sapiens)		5 / 10
HIS A  74
TYR A 159
LEU A 156
GLN A 115
GLY A 112
1.78A19.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		3i6k BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 12
HIS F  84
ILE F  35
SER F  57
SER F  52
ILE E  23
1.70A14.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
ILE D 106
ALA D 173
ILE D 136
ILE D 200
PHE D 112
1.56A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		3r24 NSP10 AND NSP11
(SARSr-CoV)		5 / 12
HIS B  83
LEU B 112
ILE B  81
SER B  15
ILE B  38
1.67A17.91
 ZN  B 998 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		3sci ACE2
(Homo
sapiens)		6 / 12
TYR B 381
HIS B 401
MET B 408
LEU B 554
MET B 383
MET B 323
1.78A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3sci ACE2
(Homo
sapiens)		5 / 10
LEU B 560
ALA B 396
VAL B 404
LEU B 320
MET B 383
1.53A21.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3sci ACE2
(Homo
sapiens)		5 / 10
TYR B 521
PHE B 525
LEU B 554
MET B 408
GLY B 377
1.59A21.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		3scj ACE2
(Homo
sapiens)		6 / 12
TYR A 381
HIS A 401
MET A 408
LEU A 554
MET A 383
MET A 323
1.80A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		6 / 12
TYR A 381
HIS A 401
MET A 408
LEU A 554
MET A 383
MET A 323
1.79A19.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
HIS B 373
LEU B 418
ILE B 291
ILE B 446
GLN B 442
1.42A21.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
TYR B 521
PHE B 525
LEU B 554
MET B 408
GLY B 377
1.65A21.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3sck ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 11
HIS B 373
LEU B 418
ILE B 291
ILE B 446
GLN B 442
1.41A21.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 10
LEU B 560
ALA B 396
VAL B 404
LEU B 320
MET B 383
1.49A21.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3to2 MD3-C9 PEPTIDE
DERIVED FROM
MEMBRANE
GLYCOPROTEIN
MHC CLASS I ANTIGEN
(Homo
sapiens;
SARS-COV
TJF)		5 / 10
ALA A 140
ILE A 124
VAL C   9
ALA C   8
LEU C   6
1.57A20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		3to2 MD3-C9 PEPTIDE
DERIVED FROM
MEMBRANE
GLYCOPROTEIN
MHC CLASS I ANTIGEN
(Homo
sapiens;
SARS-COV
TJF)		5 / 10
LEU C   6
ALA C   8
VAL A 152
ALA A 153
LEU A 160
1.60A3.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
MET B 130
SER B 144
MET B 165
GLN B 192
PHE B 185
1.79A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		4mm3 UBIQUITIN
(Homo
sapiens)		5 / 12
LEU A  50
ILE A  23
VAL A   5
ILE A  36
GLN A  41
1.47A13.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		5 / 10
ALA A 177
ILE A 126
ALA A 132
GLN A 134
PHE A 137
1.63A20.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		5c8s GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
MET B 195
LEU B 185
SER A  11
GLN B 246
PHE B  73
1.70A20.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
LEU B 109
ALA B 270
ALA B 187
LEU B 192
PHE B  89
1.49A19.21
None
None
MG  B 604 (-3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		5c8s GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
MET B 195
LEU B 185
SER A  11
GLN B 246
PHE B  73
1.60A20.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
TYR B 197
ALA B 274
PHE B  89
LEU B 109
GLY B  93
1.76A20.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
TYR B 197
ALA B 274
PHE B  89
LEU B 109
GLY B  93
1.70A20.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 10
LEU B 109
ALA B 270
ALA B 187
LEU B 192
PHE B  89
1.42A19.36
None
None
MG  B 604 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
TYR D 511
LEU D 519
ILE D 510
PHE D 445
ILE D 474
1.60A20.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
TYR A  84
ILE A 152
LEU A 133
ALA A 132
PHE A 148
1.47A23.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
TYR A  84
ILE A 152
LEU A 133
ALA A 132
PHE A 148
1.48A23.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5f22 NSP8
NSP7
(SARSr-CoV)		5 / 10
LEU B 108
ALA B 155
ILE B 111
LEU A  22
MET A  67
1.63A16.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 10
LEU B 109
ALA B 270
ALA B 187
LEU B 192
PHE B  89
1.43A20.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 10
TYR C 197
ALA C 274
PHE C  89
LEU C 109
GLY C  93
1.71A20.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 12
TYR B 511
LEU B 519
ILE B 510
PHE B 445
ILE B 474
1.54A21.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.66A18.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
TYR B  84
ILE B 152
LEU B 133
ALA B 132
PHE B 148
1.43A23.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
TYR B  84
ILE B 152
LEU B 133
ALA B 132
PHE B 148
1.41A23.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5x4r S PROTEIN
(MERS-CoV)		5 / 11
ILE A 295
LEU A 149
ILE A 256
VAL A 315
ILE A 120
1.59A19.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		5x4s SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER A 165
SER A 120
GLN A 147
PHE A 138
ILE A 234
1.65A19.50
None
NAG  A 602 (-3.3A)
NAG  A 602 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
ILE B 905
VAL B1047
PHE B1034
ILE B 913
PHE B 782
1.30A14.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
LEU B 831
SER A 607
SER A 577
GLN B 835
ILE B 832
1.69A15.14
None
None
None
None
NAG  A1301 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
LEU A 994
ALA A 997
ILE A 752
ALA A 938
LEU A 944
1.60A15.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 11
LEU A 898
ILE A 905
VAL A1047
ILE A 913
PHE A 782
1.48A14.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
PHE B 870
LEU B 859
MET B 770
GLN B 769
GLY A 682
1.63A14.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5x5f S PROTEIN
(MERS-CoV)		5 / 11
LEU A1078
ALA A1037
VAL A 802
ILE A 799
GLN A1085
1.53A13.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE B 905
VAL B1047
PHE B1034
ILE B 913
PHE B 782
1.32A14.31
ILE  B 905 ( 0.7A)
VAL  B1047 ( 0.6A)
PHE  B1034 ( 1.3A)
ILE  B 913 ( 0.4A)
PHE  B 782 ( 1.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		5zvm PAN-COV INHIBITORY
PEPTIDE EK1
SPIKE GLYCOPROTEIN
(SARSr-CoV;
synthetic
construct)		5 / 12
LEU a  25
ILE B 916
SER a  35
GLN B 915
ILE a  29
1.68A7.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6acc SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LEU B 898
ILE B 905
VAL B1047
ILE B 913
PHE B 782
1.31A14.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE A 905
VAL A1047
PHE A1034
ILE A 913
PHE A 782
1.30A14.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6acg ACE2
(Homo
sapiens)		5 / 11
HIS D 540
ILE D 446
ILE D 407
GLN D 522
PHE D 523
1.56A21.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
LEU C 286
ILE C 295
VAL C 276
ALA C 275
LEU C  54
1.46A15.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU B 194
ILE B 115
MET B 107
SER B 111
ILE B 228
1.47A15.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
ALA A 866
PHE A 870
LEU A 859
GLN A 769
GLY B 682
1.68A14.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
LEU A 994
ALA A 997
ILE A 752
ALA A 940
LEU A 944
1.52A15.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE B 905
VAL B1047
PHE B1034
ILE B 913
PHE B 782
1.29A14.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
LEU A 804
ILE A 787
SER A 703
SER A 914
GLN A 786
1.56A15.61
None
None
None
None
NAG  A1305 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
LEU C 898
ILE C 905
VAL C1047
ILE C 913
PHE C 782
1.49A14.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
LEU A 804
ILE A 787
SER A 703
SER A 914
GLN A 786
1.53A15.61
None
None
None
None
NAG  A1305 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
LEU B 804
ILE B 787
SER B 703
SER B 914
GLN B 786
1.42A15.76
None
None
None
None
NAG  B1310 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
LEU B 898
ILE B 905
VAL B1047
ILE B 913
PHE B 782
1.35A13.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
LEU B 804
ILE B 787
SER B 703
SER B 914
GLN B 786
1.42A15.76
None
None
None
None
NAG  B1315 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
PHE A 888
LEU A 898
MET A 882
GLN A 883
PHE A 880
1.62A14.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
LEU B 745
ALA B 748
ALA A 940
LEU A 944
GLN A 992
1.49A15.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ILE B 905
VAL B1047
PHE B1034
ILE B 913
PHE B 782
1.17A13.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 12
HIS B  84
MET A  12
ILE B  35
SER B  57
SER B  52
1.60A14.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6jyt HELICASE
(SARSr-CoV)		5 / 10
ALA B 362
ILE B 334
VAL B 314
ALA B 312
PHE B 343
1.52A20.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6jyt HELICASE
(SARSr-CoV)		5 / 12
LEU A 526
SER A 535
SER A 513
GLN A 518
ILE A 545
1.75A20.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6lu7 MAIN PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.62A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 12
LEU C 966
ILE C 973
SER B 974
PHE B 970
ILE B1169
1.65A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 11
ILE E1169
ALA E 972
ILE E 973
ILE D1169
PHE E 970
1.48A18.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.64A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6lzg ACE2
(Homo
sapiens)		6 / 12
TYR A 381
HIS A 401
MET A 408
LEU A 554
MET A 383
MET A 323
1.77A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU B 368
ILE B 358
SER B 399
PHE B 342
ILE B 434
1.76A21.45
None
None
None
NAG  B 601 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.64A23.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m17 ACE2
(Homo
sapiens)		5 / 10
TYR B 521
PHE B 525
LEU B 554
MET B 408
GLY B 377
1.68A17.49
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
HIS C 524
ILE C 522
SER C 307
SER C 290
GLN C  94
1.56A21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.67A21.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_B_VDNB102_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6m18 ACE2
(Homo
sapiens)		5 / 12
TYR B 381
HIS B 401
MET B 408
LEU B 554
MET B 383
1.71A19.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m1d ACE2
(Homo
sapiens)		5 / 11
ILE D 618
ALA D 650
VAL D 700
ILE D 694
PHE D 683
1.50A16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6m1d ACE2
(Homo
sapiens)		5 / 12
LEU D 418
MET D 408
MET D 376
PHE D 314
ILE D 421
1.60A19.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.62A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL B 202
ALA B 206
LEU B 208
MET B 264
PHE B 230
1.61A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL C 202
ALA C 206
LEU C 208
MET C 264
PHE C 230
1.66A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL D 202
ALA D 206
LEU D 208
MET D 264
PHE D 230
1.64A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.64A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m71 NSP12
(SARS-CoV-2)		5 / 12
ILE A 548
LEU A 862
VAL A 844
PHE A 441
ILE A 847
1.74A15.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.68A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.74A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 12
MET A 519
LEU A 372
MET B  90
PHE A 506
ILE A 562
1.76A17.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
ALA C 866
PHE C 870
LEU C 859
GLN C 769
GLY A 682
1.68A13.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ILE C 905
VAL C1047
PHE C1034
ILE C 913
PHE C 782
1.25A13.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
LEU B 994
ALA B 997
ILE B 752
ALA B 940
LEU B 944
1.52A14.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6nur NSP12
NSP7
(SARSr-CoV)		6 / 10
HIS C  36
TYR A 420
ALA A 550
PHE A 440
LEU A 437
GLY A 841
1.73A15.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6nus NSP12
NSP8
(SARSr-CoV)		5 / 12
HIS A 381
MET B  87
ILE A 539
SER A 501
SER A 564
1.76A17.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6nus NSP12
(SARSr-CoV)		5 / 10
TYR A 374
LEU A 361
VAL A 342
ALA A 379
LEU A 329
1.54A16.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU A 368
ILE A 358
SER A 399
PHE A 342
ILE A 434
1.49A14.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE C 923
VAL C1065
PHE C1052
ILE C 931
PHE C 800
1.22A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU B 916
ILE B 923
VAL B1065
ILE B 931
PHE B 800
1.35A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
HIS C 207
TYR C  37
ALA C  93
GLY C  89
PHE C 194
1.65A13.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU B1012
ALA B1015
ILE B 770
ALA B 958
LEU B 962
1.54A15.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vw1 ACE2
(Homo
sapiens)		5 / 10
TYR B 521
PHE B 525
LEU B 554
MET B 408
GLY B 377
1.60A21.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU A  73
ALA A  95
ILE A  86
ILE A 100
PHE A 123
1.53A22.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 298
ILE B 296
VAL B 237
PHE B 233
1.44A22.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxs NSP3
(SARS-CoV-2)		5 / 10
HIS A  86
TYR A  68
ALA A  50
LEU A  43
GLY A  79
1.68A
None
None
None
None
SO4  A 201 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxs NSP3
(SARS-CoV-2)		5 / 10
HIS B  86
TYR B  68
ALA B  50
LEU B  43
GLY B  79
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
HIS B 207
TYR B  37
ALA B  93
GLY B  89
PHE B 194
1.75A13.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU B 916
ILE B 923
VAL B1065
ILE B 931
PHE B 800
1.38A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE B 923
VAL B1065
PHE B1052
ILE B 931
PHE B 800
1.23A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU B1012
ALA B1015
ILE B 770
ALA B 958
LEU B 962
1.59A15.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 806
ILE C 794
SER B 711
PHE C 797
ILE C 882
1.43A13.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU B1012
ALA B1015
ILE B 770
ALA B 958
LEU B 962
1.62A15.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU A 916
ILE A 923
VAL A1065
ILE A 931
PHE A 800
1.38A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ILE C 923
VAL C1065
PHE C1052
ILE C 931
PHE C 800
1.24A14.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 10
TYR L  32
TYR H  32
ALA L  34
GLN L  89
GLY H  35
1.75A17.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 10
LEU C 513
VAL C 524
ALA C 522
LEU C 390
PHE C 515
1.69A19.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 12
LEU C 368
ILE C 358
SER C 399
PHE C 342
ILE C 434
1.74A15.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.63A
None
None
None
None
SAM  A7104 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.64A
None
None
None
EDO  A7102 (-4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.69A
None
None
None
None
SAM  A7104 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
MET A6929
1.74A
None
None
None
EDO  A7102 (-4.8A)
SAM  A7104 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.63A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w6y NSP3
(SARS-CoV-2)		5 / 10
HIS B  86
TYR B  68
ALA B  50
LEU B  43
GLY B  79
1.74A
None
None
MES  B 201 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.67A17.13
None
None
None
None
SAM  C7105 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.72A17.13
None
None
None
None
SAM  A7102 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
PHE C6948
ILE C6955
1.65A17.13
None
None
None
FMT  C7115 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP10
(SARS-CoV-2)		5 / 10
LEU D4328
ALA D4277
VAL D4274
ALA B4279
PHE B4272
1.69A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.67A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.66A17.13
None
None
None
None
SAM  A7102 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w75 NSP16
(SARS-CoV-2)		5 / 11
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.73A17.13
None
None
None
None
SAM  C7105 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ILE C 123
LEU C 178
ALA C 204
VAL C 242
PHE C 173
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
TYR B  83
ILE B 151
LEU B 132
ALA B 131
PHE B 147
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
TYR B  83
ILE B 151
LEU B 132
ALA B 131
PHE B 147
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
TYR C  83
ILE C 151
LEU C 132
ALA C 131
PHE C 147
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 11
ILE C 123
LEU C 178
ALA C 204
VAL C 242
PHE C 173
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wcf NSP3
(SARS-CoV-2)		5 / 10
HIS A  86
TYR A  68
ALA A  50
LEU A  43
GLY A  79
1.74A
None
None
MES  A 201 ( 3.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU B 103
ALA B 150
ILE B 106
LEU A  17
MET A  62
1.69A16.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU A  60
ALA A  65
MET B  90
GLN B  88
PHE B  92
1.70A15.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.43A15.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE F 304
LEU F 353
ILE F 357
ILE F 292
PHE F 286
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE F 304
LEU F 353
ILE F 357
ILE F 292
PHE F 286
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE A 304
LEU A 353
ILE A 357
ILE A 292
PHE A 286
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR C 298
LEU C 353
SER D 310
PHE C 286
ILE D 320
1.73A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE C 304
LEU D 331
ILE D 320
ILE C 292
PHE D 315
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE B 304
LEU A 331
ILE A 320
ILE B 292
PHE A 315
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE D 304
LEU D 353
ILE D 357
ILE D 292
PHE D 286
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR B 298
LEU B 353
SER A 310
PHE B 286
ILE A 320
1.72A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE C 304
LEU C 353
ILE C 357
ILE C 292
PHE C 286
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU C 331
ALA D 336
ILE D 337
ILE D 320
PHE C 314
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE E 304
LEU E 353
ILE E 357
ILE E 292
PHE E 286
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE B 304
LEU B 353
ILE B 357
ILE B 292
PHE B 286
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE D 304
LEU D 353
ILE D 357
ILE D 292
PHE D 286
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU F 331
ALA E 336
ILE E 337
ILE E 320
PHE F 314
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE A 304
LEU B 331
ILE B 320
ILE A 292
PHE B 315
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR E 298
LEU E 353
SER F 310
PHE E 286
ILE F 320
1.66A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE E 304
LEU E 353
ILE E 357
ILE E 292
PHE E 286
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE D 304
LEU C 331
ILE C 320
ILE D 292
PHE C 315
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE B 304
LEU B 353
ILE B 357
ILE B 292
PHE B 286
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LEU C 331
ALA D 336
ILE D 337
ILE D 320
PHE C 314
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
ILE A 304
LEU A 353
ILE A 357
ILE A 292
PHE A 286
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE D 304
LEU C 331
ILE C 320
ILE D 292
PHE C 315
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE C 304
LEU C 353
ILE C 357
ILE C 292
PHE C 286
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
LEU F 331
ALA E 336
ILE E 337
ILE E 320
PHE F 314
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR D 298
LEU D 353
SER C 310
PHE D 286
ILE C 320
1.68A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR A 298
LEU A 353
SER B 310
PHE A 286
ILE B 320
1.70A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE B 304
LEU A 331
ILE A 320
ILE B 292
PHE A 315
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
TYR F 298
LEU F 353
SER E 310
PHE F 286
ILE E 320
1.72A12.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
ILE E 304
LEU F 331
ILE F 320
ILE E 292
PHE F 315
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.66A
None
None
None
None
SAH  C7102 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
PHE C6948
ILE C6955
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.73A
None
None
None
None
SAH  C7102 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.74A
None
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
MET A6929
1.80A
None
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt NSP10
(SARS-CoV-2)		5 / 10
LEU D4328
ALA D4277
VAL D4274
ALA B4279
PHE B4272
1.70A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.68A
None
None
None
None
SAH  A7102 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.67A
None
None
None
None
SFG  A7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP10
(SARS-CoV-2)		5 / 10
LEU D4328
ALA D4277
VAL D4274
ALA B4279
PHE B4272
1.70A18.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 11
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.72A
None
None
None
None
SFG  C7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
ILE C6951
MET C6929
1.65A
None
None
None
None
SFG  C7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 12
TYR C6979
HIS C7023
ALA C6990
PHE C6948
ILE C6955
1.67A
None
None
None
FMT  C7105 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wkq NSP16
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.73A
None
None
None
None
SFG  A7103 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 228
ILE B 223
VAL B 339
PHE B 233
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 332
VAL B 321
ILE B 296
PHE B 342
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE A 328
LEU A 298
ILE A 306
MET A 331
PHE A 330
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE A 307
LEU A 228
ILE A 223
VAL A 339
PHE A 233
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE B 307
LEU B 228
ILE B 223
VAL B 339
PHE B 233
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE A 307
LEU A 332
VAL A 321
ILE A 296
PHE A 342
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
LEU B 228
ILE B 223
VAL B 237
LEU B 215
PHE B 222
1.67A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
HIS A 250
LEU A 255
ILE A 253
ILE A 223
MET A 219
1.58A
U5P  A 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
LEU A 228
ILE A 223
VAL A 237
LEU A 215
PHE A 222
1.63A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
ILE B 223
VAL B 237
PHE B 303
ILE B 253
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 307
LEU A 228
ILE A 223
VAL A 339
PHE A 233
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
HIS B 250
LEU B 255
ILE B 253
ILE B 223
MET B 219
1.57A
U5P  B 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 307
LEU B 298
ILE B 296
VAL B 237
PHE B 233
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU A  73
ALA A  95
ILE A  86
ILE A 100
PHE A 123
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
TYR B  89
LEU B 163
ILE B  64
ALA B  95
LEU B  73
1.77A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 307
LEU A 298
ILE A 296
VAL A 237
PHE A 233
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LEU A  73
ALA A  95
ILE A  86
ILE A 100
PHE A 123
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
HIS A 250
LEU A 255
ILE A 253
ILE A 223
MET A 219
1.57A
U5P  A 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LEU B  73
ALA B  95
ILE B  86
ILE B 100
PHE B 123
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
HIS B 250
LEU B 255
ILE B 253
ILE B 223
MET B 219
1.59A
U5P  B 401 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 10
TYR A  89
LEU A 163
ILE A  64
ALA A  95
LEU A  73
1.75A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU B  73
ALA B  95
ILE B  86
ILE B 100
PHE B 123
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 328
LEU A 298
ILE A 306
MET A 331
PHE A 330
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 307
LEU A 332
VAL A 321
ILE A 296
PHE A 342
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.65A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.76A
None
None
APR  D 201 (-3.7A)
None
APR  D 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.69A
None
None
APR  D 201 (-3.7A)
None
APR  D 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
HIS A  86
TYR A  68
ALA A  50
LEU A  43
GLY A  79
1.71A
None
None
APR  A 201 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.72A
None
None
APR  A 201 (-3.7A)
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.77A
None
None
APR  C 201 (-3.7A)
None
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.78A
None
None
APR  A 201 (-3.7A)
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.75A
None
None
APR  B 201 (-3.7A)
None
APR  B 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.68A
None
None
APR  B 201 (-3.7A)
None
APR  B 201 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.65A
None
None
None
None
SAH  A7101 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
TYR A6979
HIS A7023
ALA A6990
ILE A6951
MET A6929
1.71A
None
None
None
None
SAH  A7101 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
MET A6929
1.78A
None
None
None
None
SAH  A7101 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
TYR A6979
HIS A7023
ALA A6990
PHE A6948
ILE A6955
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
TYR B 149
ILE B 119
ALA B 102
LEU B  95
MET A  52
1.78A16.09
None
None
EDO  B 302 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
TYR D 149
ILE D 119
ALA D 102
LEU D  95
MET C  52
1.79A16.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU D 103
ALA D 150
ILE D 106
LEU C  17
MET C  62
1.62A16.09
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU B 103
ALA B 150
ILE B 106
LEU A  17
MET A  62
1.64A16.09
None
EDO  B 302 (-3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.68A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 11
TYR A  83
ILE A 151
LEU A 132
ALA A 131
PHE A 147
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 11
ILE A 123
LEU A 178
ALA A 204
VAL A 242
PHE A 173
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
TYR A  83
ILE A 151
LEU A 132
ALA A 131
PHE A 147
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.65A18.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.14A12.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.20A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
LEU D 103
ALA D 150
ILE D 106
LEU C  17
MET C  62
1.65A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
LEU B 103
ALA B 150
ILE B 106
LEU A  17
MET A  62
1.67A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
LEU A  60
ALA A  65
VAL A  16
MET B  90
PHE B  92
1.19A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.79A19.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 10
TYR L  38
TYR H  32
ALA L  40
GLN L  95
GLY H  35
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR E 380
LEU E 425
ALA E 411
ILE E 410
LEU E 368
1.73A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 10
TYR C  38
TYR B  32
ALA C  40
GLN C  95
GLY B  35
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU A 368
ILE A 358
SER A 399
PHE A 342
ILE A 434
1.79A19.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU A 513
VAL A 524
ALA A 522
LEU A 390
PHE A 515
1.66A19.24
None
None
None
DMS  A 905 (-4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU E 513
VAL E 524
ALA E 522
LEU E 390
PHE E 515
1.62A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR A 380
LEU A 425
ALA A 411
ILE A 410
LEU A 368
1.76A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR E 380
LEU E 425
ALA E 411
ILE E 410
LEU E 368
1.76A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.66A19.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		5 / 10
TYR L  38
TYR H  32
ALA L  40
GLN L  95
GLY H  35
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU E 513
VAL E 524
ALA E 522
LEU E 390
PHE E 515
1.59A19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.67A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU A 513
VAL A 524
ALA A 522
LEU A 390
PHE A 515
1.63A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 10
TYR L  38
TYR H  32
ALA L  40
GLN L  95
GLY H  35
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU E 368
ILE E 358
SER E 399
PHE E 342
ILE E 434
1.79A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR A 380
LEU A 425
ALA A 411
ILE A 410
LEU A 368
1.73A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU A 368
ILE A 358
SER A 399
PHE A 342
ILE A 434
1.79A19.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU E 513
VAL E 524
ALA E 522
LEU E 390
PHE E 515
1.61A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR E 380
LEU E 425
ALA E 411
ILE E 410
LEU E 368
1.73A19.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		5 / 10
TYR C  38
TYR B  32
ALA C  40
GLN C  95
GLY B  35
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 12
ALA A 206
PHE A   8
ILE A 106
GLN A 110
PHE A 294
1.78A
None
None
None
PEG  A 405 ( 3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.67A23.22
PEG  A 405 (-4.1A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS A 119
TYR A  68
ALA A 112
LEU A  75
GLN D 118
1.77A
None
None
None
None
EDO  D 201 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
LEU D  75
ILE D  69
LEU D  53
MET D  61
GLN D  62
1.67A18.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.62A
None
None
APR  A 201 ( 3.7A)
APR  A 201 ( 4.8A)
APR  A 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.71A
None
None
APR  D 201 (-3.4A)
None
APR  D 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE E  18
LEU E 140
ALA E 129
VAL E 155
ILE E  23
1.72A
None
None
APR  E 201 (-3.5A)
APR  E 201 ( 4.9A)
APR  E 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
LEU D  75
ILE D  69
LEU D  53
MET D  61
GLN D  62
1.65A18.51
EDO  D 202 (-4.6A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.62A
None
None
APR  B 201 (-3.6A)
None
APR  B 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.68A
None
None
APR  A 201 ( 3.7A)
APR  A 201 ( 4.8A)
APR  A 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE B  18
LEU B 140
ALA B 129
VAL B 155
ILE B  23
1.68A
None
None
APR  B 201 (-3.6A)
None
APR  B 201 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.67A
None
None
APR  C 201 (-3.6A)
APR  C 201 ( 4.9A)
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE D  18
LEU D 140
ALA D 129
VAL D 155
ILE D  23
1.65A
None
None
APR  D 201 (-3.4A)
None
APR  D 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
LEU B  75
ILE B  69
LEU B  53
MET B  61
GLN B  62
1.67A18.51
None
None
None
None
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.60A
None
None
APR  C 201 (-3.6A)
APR  C 201 ( 4.9A)
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE C  18
LEU C 140
ALA C 129
VAL C 155
ILE C  23
1.78A
None
None
None
EDO  C 206 ( 4.2A)
EDO  C 206 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS C 119
TYR C  68
ALA C 112
LEU C  75
GLN A 118
1.78A
None
None
None
None
EDO  A 202 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_B_VDNB1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS C  86
TYR C  68
ALA C  50
LEU C  43
GLY C  79
1.68A
None
None
MES  C 201 ( 3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
ILE A  18
LEU A 140
ALA A 129
VAL A 155
ILE A  23
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 10
HIS A 119
TYR A  68
ALA A 112
LEU A  75
GLN C 118
1.76A
None
None
None
None
EDO  A 204 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.62A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
(SARS-CoV-2)		5 / 12
TYR A  87
HIS A  99
PHE A 219
ILE A 201
MET A 196
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.78A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
NSP7
(SARS-CoV-2)		6 / 10
HIS C  36
TYR A 420
ALA A 550
PHE A 440
LEU A 437
GLY A 841
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 12
MET A 519
LEU A 372
MET B  90
PHE A 506
ILE A 562
1.73A17.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7btf NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.67A17.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 10
VAL A 202
ALA A 206
LEU A 208
MET A 264
PHE A 230
1.63A23.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.77A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP7
NSP8
(SARS-CoV-2)		5 / 10
LEU D 103
ALA D 150
ILE D 106
LEU C  17
MET C  62
1.57A18.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
TYR A  87
HIS A  99
PHE A 219
ILE A 201
MET A 196
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.68A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
ALA A 195
ILE A 201
VAL A  96
ALA A  97
PHE A 222
1.76A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XP0_A_VDNA201_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 787
LEU A 172
ILE A 171
ALA A 130
LEU A 127
1.66A17.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1XOT_A_VDNA101_1
(CAMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE 4B)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 12
MET A 519
LEU A 372
MET B  90
PHE A 506
ILE A 562
1.80A17.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
NSP7
(SARS-CoV-2)		6 / 10
HIS C  36
TYR A 420
ALA A 550
PHE A 440
LEU A 437
GLY A 841
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UHO_A_VDNA1000_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 122
TYR A 175
ALA A 125
LEU A 131
GLY A 179
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3B2R_A_VDNA1_1
(CGMP-SPECIFIC
3',5'-CYCLIC
PHOSPHODIESTERASE)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
TYR A  87
HIS A  99
PHE A 219
ILE A 201
MET A 196
1.70A
None